JP4194669B2 - Hair treatment agent - Google Patents
Hair treatment agent Download PDFInfo
- Publication number
- JP4194669B2 JP4194669B2 JP24137996A JP24137996A JP4194669B2 JP 4194669 B2 JP4194669 B2 JP 4194669B2 JP 24137996 A JP24137996 A JP 24137996A JP 24137996 A JP24137996 A JP 24137996A JP 4194669 B2 JP4194669 B2 JP 4194669B2
- Authority
- JP
- Japan
- Prior art keywords
- cuticle
- hair
- extract
- protein
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004209 hair Anatomy 0.000 title claims description 93
- 238000011282 treatment Methods 0.000 title claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 94
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 239000000284 extract Substances 0.000 claims description 88
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 210000004207 dermis Anatomy 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 claims description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 88
- 238000004519 manufacturing process Methods 0.000 description 54
- 238000002360 preparation method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 239000003638 chemical reducing agent Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000003277 amino acid sequence analysis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003700 hair damage Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 210000002268 wool Anatomy 0.000 description 3
- ZNEMGFATAVGQSF-UHFFFAOYSA-N 1-(2-amino-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-5-yl)-2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound NC=1SC2=C(CN(CC2)C(CC=2OC(=NN=2)C=2C=NC(=NC=2)NC2CC3=CC=CC=C3C2)=O)N=1 ZNEMGFATAVGQSF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 2
- ZZTCCAPMZLDHFM-UHFFFAOYSA-N ammonium thioglycolate Chemical compound [NH4+].[O-]C(=O)CS ZZTCCAPMZLDHFM-UHFFFAOYSA-N 0.000 description 2
- 229940075861 ammonium thioglycolate Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 101710081227 Protein cortex Proteins 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101000654530 Tupaia virus (isolate Tupaia/Thailand/-/1986) Small hydrophobic protein Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、毛髪損傷の予防または修復に有用な、毛髪処理剤に関する。
【０００２】
【従来の技術】
毛髪がパーマ処理等により損傷を受けキューティクルの捲れや枚数の減少が起こることが知られている。この際、毛髪から蛋白質が溶出されるという報告はあるが、その由来については不明であった。
【０００３】
また、損傷毛髪の修繕剤として従来シリコンなどの毛髪コート剤や毛髪ケラチン、その加水分解物またはその誘導体を補う試みが行われてきている。しかし、毛髪ケラチンは不溶性の蛋白質でパーマ処理等により溶出される蛋白質とは全く異なる物性を持つため充分な損傷毛髪の修繕効果を得ることは困難なのが実情である。
【０００４】
【発明が解決しようとする課題】
本発明者等はかかる事情に鑑み鋭意検討した結果、毛小皮から抽出操作を行うことにより得られる、毛髪の表層を構成する特定の蛋白質が上記の毛髪の損傷により溶出される蛋白質の成分の一つであり、また該蛋白質が毛髪を還元剤を含む緩衝液で抽出することにより効率良く製造できること、さらには該蛋白質を含有せしめた毛髪処理剤として有用であることを見い出し本発明を完成するに至ったものであって、その目的は、毛髪損傷予防あるいは損傷毛髪修復に有用な、毛髪処理剤を提供するにある。
【０００５】
【課題を解決するための手段】
従って、上述の目的は、哺乳類の毛小皮より抽出される、毛小皮由来抽出物、又はさらに蛋白質のＳＨ基の全部又は一部を修飾することによって得られる毛小皮由来抽出物誘導体を配合することを特徴とする毛髪処理剤によって達成される。
【０００６】
【発明の実施の形態】
以下、本発明の構成について詳説する。
【０００７】
本発明で用いられる毛小皮（キューティクル）の取得方法としては、公知の毛髪から分離して得る方法が挙げられる。例えば、毛髪を水中で振とう、攪拌あるいは超音波処理することにより、物理的に剥離することができる（Journal of the Society of Cosmetic Chemists,25巻，13頁，1974年参照）。剥離した毛小皮は、ガーゼやメッシュで濾過することにより、毛髪から分離した後、遠心分離又は濾過することにより収集することができる。なお、本発明で用いる毛髪は人毛のほか羊毛、豚毛などの由来のものが挙げられる。
【０００８】
本発明の毛小皮由来抽出物の製造方法としては、例えば収集した毛髪より分離して得た毛小皮を、(1)還元剤のみを含む緩衝液， (2)還元剤及び可溶化剤を含む緩衝液、等の抽出液で抽出する方法等が挙げられる。特に(1)の還元剤のみを含む緩衝液中で抽出操作を行うと、より混在物の少ない毛小皮由来抽出物を得ることができるので好ましい。
【０００９】
抽出操作は、毛小皮の抽出緩衝液の液性をアルカリ性として行う。温度を25℃から 100℃の条件として行うことが好ましい。
【００１０】
また、毛小皮から毛小皮由来抽出物を製造する際には毛小皮を抽出液中で攪拌するか、ホモジナイザー等を用いて毛小皮を抽出液中擦り潰すと、効率良く本発明の毛小皮由来抽出物が得られ好ましい。
【００１１】
本発明に用いられる還元剤としては、メルカプトエタノール、ジチオスレイトール、亜硫酸ナトリウム、チオグリコール酸アンモニウム等が挙げられる。
【００１２】
本発明に用いられる還元剤の、単独使用の濃度としては、緩衝液総量の１〜３重量％が好ましい。
【００１３】
抽出液に用いられる可溶化剤としては、周知公用の変性剤、界面活性剤等の可溶化剤等を用いることができ、例えば変性剤としては尿素、塩酸グアニジン等が挙げられ、界面活性剤としてはドデシル硫酸ナトリウム等が挙げられる。
【００１４】
本発明の毛小皮由来抽出物誘導体の製造方法としては、本発明の毛小皮由来抽出物に含有される蛋白質のＳＨ基を例えば、モノヨード酢酸あるいはエチレンイミン等で修飾する通常の方法が挙げられる。
【００１５】
本発明の毛小皮由来抽出物誘導体は、還元剤や可溶化剤が存在しなくても水に溶解するので広い範囲に応用することができる。
【００１６】
本発明の毛小皮由来抽出物、並びに毛小皮由来抽出物誘導体自体もＳ−Ｓ架橋又はＳＨ基を多量に含有した蛋白質であるので、直接シャンプー、リンス、ヘアートリートメント等の毛髪処理剤に配合することによって、毛髪の保護成分として使用することも可能である。
【００１７】
本発明の毛小皮由来抽出物、毛小皮由来抽出物誘導体を含む毛髪処理剤の剤形としてはトリートメント、リンス、シャンプー、ヘアクリーム、ヘアーローション、ヘアーパック、パーマネント用剤等、毛髪に対して用いる各種のものが挙げられる。
【００１８】
本発明の毛小皮由来抽出物および毛小皮由来抽出物誘導体の含有量は、組成物の総量を基準として0.01重量％〜５重量％が好ましく0.1 重量％〜１重量％が特に好ましい。
【００１９】
この他、本発明の毛小皮由来抽出物、並びに毛小皮由来抽出物誘導体は、例えば毛小皮を特異的に認識する抗体を作製する際の抗原としても有用である。
【００２０】
【実施例】
以下、実施例、比較例によって本発明を更に詳細に説明する。
【００２１】
製造例１、２及び参考例１、２（ヒト毛小皮からの毛小皮由来抽出物、毛小皮由来抽出物誘導体、毛小皮特異蛋白質及び毛小皮特異蛋白質誘導体の製造）
（１）ヒト毛小皮 800mgを、8M尿素及び 0.2M 2-メルカプトエタノールを含む0.2Mトリス（pH 9.5）3ml に加え、50℃１時間インキュベートした後、ガラスホモジナイザーを用いて擦り潰した。更に50℃１時間インキュベートした後、遠心分離（10,000 g）して上清を集め、毛小皮由来抽出物（蛋白質量として21mg；製造例１）を得た。
【００２２】
（２）また、この毛小皮由来抽出物（製造例１）の半量にモノヨード酢酸75mgを加え、トリスでｐH 9.0 とし、遮光下室温で1.5 hr攪拌した。10mMトリス−塩酸緩衝液（pH 8.0）により透析して毛小皮由来抽出物（カルボキシメチル化）誘導体（製造例２）を得た。
【００２３】
（３）毛小皮特異蛋白質ならびにその毛小皮特異蛋白質（カルボキシメチル化）誘導体はSDS-ポリアクリルアミド電気泳動により分離した。上記によって得られた製造例１又は２の抽出物を、6M尿素を含む15％ゲルを用いて電気泳動した後、ポリビニリデンジフルオライド（PVDF）膜に転写し、得られた毛小皮抽出物の分子量約7,000 のバンドならびにその毛小皮抽出物誘導体の分子量約15,000のバンドを切り取り、酢酸／アセトニトリル／水（7:2:1)の混合溶液で抽出し、毛小皮特異蛋白質（参考例１）及び毛小皮特異蛋白質（カルボキシメチル化）誘導体（参考例２）を得た。
【００２４】
PVDF膜上の毛小皮特異蛋白質（カルボキシメチル化）誘導体を0.5%ポリビニルピロリドンで処理した後、トリプシン（プロメガ社製）を加え24時間37℃で反応させた。得られた分解物を下記条件の逆相液体クロマトグラフィーに付し、保持時間14.2分及び18.3分の画分を分取した。
【００２５】
カラム：A-312 ODS（6.O×150 mm, YMC 社製）
溶出：水−アセトニトリル−トリフルオロ酢酸 (90:10:0.1)から水−アセトニトリル−トリフルオロ酢酸 (30:70:0.1)の直線的濃度勾配（60分間かけて濃度勾配をかける）
流速：2.O ml/min
検出：220 nmにおける吸光度
【００２６】
得られた画分を減圧乾燥後、アプライドバイオシステムズ社製471A気相プロテインシークエンサーでアミノ酸配列を分析し、下記の結果を得た。
【００２７】
保持時間14.2分の画分のアミノ酸配列分析結果：
【００２８】
【化１】
保持時間18.3分の画分のアミノ酸配列分析結果：
【００３０】
【化２】
（但し、Ｘは未同定のアミノ酸である。）
【００３２】
製造例３、４及び参考例３、４（ヒト毛小皮からの毛小皮由来抽出物、毛小皮由来抽出物誘導体、毛小皮特異蛋白質及び毛小皮特異蛋白質誘導体の製造）
ヒト毛小皮100 mgを用いる以外は、製造例１、２及び参考例１、２と同様にして、ヒト毛小皮からの毛小皮由来抽出物、毛小皮由来抽出物誘導体、毛小皮特異蛋白質及び毛小皮特異蛋白質誘導体を製造した（製造例３、４及び参考例３、４）。
【００３３】
得られた画分を減圧乾燥後、アプライドバイオシステムズ社製471A気相プロテインシークエンサーでアミノ酸配列を分析し、下記の結果を得た。
【００３４】
保持時間14.2分の画分のアミノ酸配列分析結果：
【００３５】
【化３】
保持時間18.3分の画分のアミノ酸配列分析結果：
【００３７】
【化４】
製造例５（変性剤及び還元剤含有緩衝液による毛小皮由来抽出物の製造）
ヒト毛小皮800 mgを、8M尿素及び 0.2M 2-メルカプトエタノールを含む0.2Mトリス（pH 9.5）3ml に加え、50℃１時間インキュベートした後、ガラスホモジナイザーを用いて擦り潰した。更に50℃１時間インキュベートした後、遠心分離（10,000 g）して上清を収集した。残渣をガラスホモジナイザーを用いて擦り潰し、50℃１時間インキュベートした後、遠心分離（10,000 g）し上清を収集する操作を、計６回繰り返し、得られた上清を集めて毛小皮由来抽出物（蛋白質量として21mg）を得た。
【００３９】
製造例６（界面活性剤及び還元剤含有緩衝液による毛小皮由来抽出物の製造）
ヒト毛小皮を抽出する溶液として、2%ドデシル硫酸ナトリウム及び 10mM ジチオスレイトールを含む0.2Mトリス（pH 9.0）3ml を用いる以外は製造例５と同様にして、毛小皮由来抽出物（蛋白質量として15mg）を得た。
【００４０】
製造例７（ヒト毛小皮からの還元剤含有緩衝液による毛小皮由来抽出物の製造）
ヒト毛小皮を抽出する溶液として、0.2M 2-メルカプトエタノールを含む0.2Mトリス（pH 9.5）3ml を用いる以外は製造例５と同様にして、毛小皮由来抽出物（蛋白質量として8.9 mg）を得た。
【００４１】
参考例５（全毛髪のパーマ液による毛小皮特異蛋白質画分の製造）
ヒト毛髪2.5gをパーマ第１液（12％チオグリコール酸アンモニウム、１％エタノールアミン、0.05％エチレンジアミン四酢酸ナトリウム、0.42％アンモニア水溶液）50mlに室温15分間浸した。５回パーマ第１液を交換して溶出液を集め、限外濾過膜を用いて濃縮し毛小皮特異蛋白質画分（蛋白質量として0.13mg）を得た。
【００４２】
製造例８、９及び参考例６、７（羊毛小皮からの毛小皮由来抽出物、毛小皮由来抽出物誘導体、毛小皮特異蛋白質及び毛小皮特異蛋白質誘導体の製造）
羊毛小皮 200mgを用い、製造例１、２及び参考例１、２の（１）と同様の方法により、毛小皮由来抽出物（蛋白質量として5.2 mg；製造例８）を得た。
【００４３】
また、この毛小皮由来抽出物（製造例８）の半量にモノヨード酢酸を25mg加える他は、製造例１、２及び参考例１、２の（２）と同様にして、毛小皮由来抽出物（カルボキシメチル化）誘導体（製造例９）を得た。
【００４４】
毛小皮特異蛋白質ならびにその毛小皮特異蛋白質（カルボキシメチル化）誘導体はSDS-ポリアクリルアミド電気泳動により分離した。上記によって得られた製造例８又は９の抽出物を、6M尿素を含む15％ゲルを用いて電気泳動した後、得られた毛小皮抽出物の分子量約7,000 のバンドならびにその毛小皮抽出物誘導体の分子量約15,000のバンドを切り取り、蛋白質溶出装置（ISCO社製、1750）を用いて抽出し、毛小皮特異蛋白質（参考例６）及び毛小皮特異蛋白質（カルボキシメチル化）誘導体（参考例７）を得た。
【００４５】
得られた画分を6M塩酸で加水分解後、日立製アミノ酸分析機でアミノ酸を分析した、下記の結果を得た。なお、システイン含量は参考例６では過ギ酸酸化後加水分解して得たシステイン酸、参考例７ではS-カルボキシメチルシステインとしての定量値である。
【００４６】
【表１】
比較製造例１（変性剤及び還元剤含有緩衝液による毛皮質由来抽出物の製造）
原料として、毛小皮を除いた毛髪、すなわち毛皮質 800mgを用いる以外は製造例１と同様にして、可溶性抽出物（蛋白質量として 160mg）を得た。
【００４８】
試験例１（蛋白質の分析）
毛小皮由来抽出物及び毛小皮特異蛋白質画分（製造例１，２，６，７，８，参考例５）ならびに毛皮質由来抽出物（比較製造例１）の蛋白質の分析結果を図１に示した。尚、毛小皮由来抽出物ならびに毛皮質由来抽出物中の蛋白質の分析は、毛小特異蛋白質（参考例１）ならびに毛小皮特異蛋白質（カルボキシメチル化）誘導体（参考例２）の分離に用いたSDS-ポリアクリルアミド電気泳動により行った。
【００４９】
製造例１，２，６，７，８ではいずれも低分子の蛋白質バンドが観察されるのに対し、比較製造例１では観察されなかった。
【００５０】
試験例２（蛋白質の分析）
試験例１と同様にして、製造例５，６，７，比較製造例１の蛋白質の分析を行い、結果を図２に示した。
【００５１】
製造例５，６，７ではいずれも低分子の蛋白質バンドが観察されるのに対し、比較製造例１では観察されなかった。
【００５２】
試験例３（毛小皮特異蛋白質の分析）
毛小皮由来抽出物中の毛小皮特異蛋白質の分析は、毛小皮特異蛋白質に対する特異抗体を用いて、ウエスタンブロッティング法により行った。毛小皮特異蛋白質に対する特異抗体は、アミノ酸配列に基づき合成して得られるペプチド抗原を免疫して得た抗血清を用いた。
【００５３】
ここでは抗原として、毛小皮特異蛋白質の部分アミノ酸配列に基いて合成した下記の構造を持つ多抗原性ペプチドを使用した。
【００５４】
【化５】
多抗原性ペプチド 250μｇを、３週間毎４回、FCA(初回免疫時) 又は、FIA(追加免疫時) と共にウサギに免疫し、初回免疫から10週後に全採血して得た抗血清を、以下の試験に用いた。
【００５６】
製造例１，２，６，７，８，参考例５で得た毛小皮由来抽出物及び毛小皮特異蛋白質画分、並びに比較製造例１で得た毛皮質由来抽出物を試験例１の方法で電気泳動した後、ＰＶＤＦ膜に転写した後、0.8%の塩化ナトリウム及び0.1%のTween 20を含む20mMトリス塩酸緩衝液で1,000倍に希釈した抗毛小皮特異蛋白質血清に浸し、１時間室温で反応させた。結合した抗体をプロテインブロッティングキット（RPN23,Amersham社製）で検出した結果を図３に示した。
【００５７】
製造例１，２，６，７，８ではいずれも低分子の蛋白質バンドへの抗毛小皮特異蛋白質特異抗体の結合が観察されるのに対し、比較製造例１では観察されなかった。従って、製造例１，２，６，７，８の毛小皮由来抽出物がいずれも毛小皮特異蛋白質を多量に含有することは明らかである。
【００５８】
試験例４（毛小皮特異蛋白質の分析）
試験例３と同様にして、製造例５〜７の毛小皮特異蛋白質の分析を行なった結果を、図４に示す。
【００５９】
製造例５〜７ではいずれも低分子の蛋白質バンドへの抗毛小皮特異蛋白質特異抗体の結合が観察されるのに対し、比較製造例１では観察されなかった。従って、製造例５〜７の毛小皮由来抽出物がいずれも毛小皮特異蛋白質を多量に含有することは明らかである。
【００６０】
実施例１〜５（毛小皮由来抽出物含有毛髪処理剤）
製造例１，２，６，７，８で得た毛小皮由来抽出物及び毛小皮由来抽出物誘導体10mgを20mM2-メルカプトエタノールを含む生理リン酸緩衝液１mlに溶解し、毛小皮由来抽出物含有の毛髪損傷修復用毛髪処理剤（実施例１〜５）を調製した。
【００６１】
試験例５（損傷毛髪に対する修復効果）
予め、パーマ処理を３回施した毛髪７束を、実施例１〜５の毛小皮由来抽出物含有毛髪損傷修復剤に各々室温で30分間浸した後、水洗した。無処理毛髪（健常毛），修復剤処理前及び処理後のパーマ処理毛髪の３種の毛髪に、キューティクルの捲れが観察し易い様にそれぞれ結び目を作り、走査型電子顕微鏡観察を行った。パーマ処理毛髪に観察されるキューティクルの捲れが、いずれの処理剤で処理することによっても健常毛程度に修復した様子が観察された。
【００６２】
実施例６〜１１（毛小皮由来抽出物含有毛髪トリートメント剤）
下記に示す組成の、製造例１，２，６，７，８，９で得た毛小皮由来抽出物及び毛小皮由来抽出物誘導体を含有した毛髪トリートメント剤（実施例６〜１１）を調製した。
【００６３】
【表２】
試験例６（毛小皮由来抽出物含有毛髪トリートメント剤の官能試験）
ヒト毛束（黒髪5g）を実施例６〜１１の毛小皮由来抽出物含有毛髪トリートメント剤に１時間浸漬後、流水で10分間水洗して風乾した。処理後毛束のくし通り、しなやかさ、風合について処理前の毛束とどちらがよいか官能評価を行った結果、いずれも毛小皮由来抽出物含有毛髪トリートメント剤で処理した毛束の方がくし通り、しなやかさ、風合が良好であった。
【００６５】
応用例１（毛小皮由来抽出物を利用した毛髪診断キット）
以下に記載した４種の溶液よりなる毛髪診断キットを作製し、ヒト毛髪で損傷度を診断した。
【００６６】
Ａ液：製造例７で得た毛小皮由来抽出物１mgを、３週間毎４回、FCA(初回免疫時) 又は、FIA(追加免疫時) と共にウサギに免疫し、初回免疫から10週後に全採血して得た抗血清を、0.05%Tween 20 を含むPBS で1,000 倍希釈して作製した。
【００６７】
Ｂ液：ペルオキシダーゼ標識ヤギ抗ウサギIgG 抗体（カッペル社製）を、0.05%Tween20を含むPBS で7,000 倍希釈して作製した。
【００６８】
Ｃ液：オルトフェニレンジアミン20mg及び過酸化水素10μｌを含む0.2Mリン酸二ナトリウム−0.1Mクエン酸緩衝液, pH 5.0（ペルオキシダーゼの基質溶液）
【００６９】
Ｄ液：生理食塩水
【００７０】
髪の傷んだ人と健常な人の毛髪10mgにＡ液を加え37℃、１時間インキュベートした。Ｄ液で６回洗浄した後、Ｂ液と室温、30分間インキュベートした。Ｄ液で６回洗浄した後、Ｃ液を加えると、傷んだ人の毛髪を入れた試験管が発色した。
【００７１】
以上の結果から、毛小皮由来抽出物を抗原として得た抗体で、毛髪の損傷状態あるいは健康状態を知ることができることは明らかである。
【００７２】
尚、Ａ液を加え37℃、１時間インキュベートした時点で、傷んだ毛髪の方は、ハリが戻る等の損傷修復効果も見られた。このことから、本発明の毛小皮由来抽出物を抗原として得た抗体は、毛髪の損傷の修復・予防にも有用であることが明らかとなった。
【００７３】
【発明の効果】
以上の結果から、本発明により、毛髪の損傷状態あるいは健康状態を知るマーカーとして，あるいは損傷毛の修復および予防用素材として有用な、毛小皮由来抽出物、毛小皮由来抽出物誘導体、及び該抽出物を配合した毛髪処理剤を提供できることは明らかである。
【図面の簡単な説明】
【図１】 毛小皮由来抽出物、毛小皮由来抽出物誘導体及び毛皮質由来抽出物を、SDS-ポリアクリルアミド電気泳動（6M尿素存在下、15％ゲル）により分離し、蛋白質をクマシーブリリアントブルー（CBBG）で染色した図面代用写真である。
矢印は、毛小皮特異蛋白質のバンドを示す。
レーン１；製造例１の蛋白質画分
レーン２；製造例２の蛋白質画分
レーン３；製造例６の蛋白質画分
レーン４；製造例７の蛋白質画分
レーン５；参考例５の蛋白質画分
レーン６；製造例８の蛋白質画分
レーン７；比較製造例１の蛋白質画分
【図２】 毛小皮由来抽出物及び毛皮質由来抽出物を、SDS-ポリアクリルアミド電気泳動（6M尿素存在下、15％ゲル）により分離し、蛋白質をクマシーブリリアントブルー（CBBG）で染色した図面代用写真である。
矢印は、毛小皮特異蛋白質のバンドを示す。
レーン１；製造例５の蛋白質画分
レーン２；製造例６の蛋白質画分
レーン３；製造例７の蛋白質画分
レーン４；比較製造例１の蛋白質画分
【図３】 毛小皮由来抽出物、毛小皮由来抽出物誘導体及び毛皮質由来抽出物の毛小皮特異蛋白質を分析した図面代用写真である。試験例１の条件で電気泳動後、PVDF膜に転写し、毛小皮特異蛋白質の特異抗体で検出した。
矢印は、毛小皮特異蛋白質のバンドを示す。
レーン１；製造例１の蛋白質画分
レーン２；製造例２の蛋白質画分
レーン３；製造例６の蛋白質画分
レーン４；製造例７の蛋白質画分
レーン５；参考例５の蛋白質画分
レーン６；製造例８の蛋白質画分
レーン７；比較製造例１の蛋白質画分
【図４】 毛小皮由来抽出物及び毛皮質由来抽出物の毛小皮特異蛋白質を分析した図面代用写真である。試験例２の条件で電気泳動後、PVDF膜に転写し、毛小皮特異蛋白質の特異抗体で検出した。
矢印は、毛小皮特異蛋白質のバンドを示す。
レーン１；製造例５の蛋白質画分
レーン２；製造例６の蛋白質画分
レーン３；製造例７の蛋白質画分
レーン４；比較製造例１の蛋白質画分[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a hair treatment agent useful for preventing or repairing hair damage.
[0002]
[Prior art]
It is known that hair is damaged by permanent treatment or the like, and cuticles curl or decrease in the number of sheets. At this time, there is a report that the protein is eluted from the hair, but its origin is unknown.
[0003]
In addition, attempts have been made to supplement hair coating agents such as silicon, hair keratin, hydrolysates thereof or derivatives thereof as repair agents for damaged hair. However, since hair keratin is an insoluble protein and has completely different physical properties from the protein eluted by perm treatment, it is difficult to obtain a sufficient repair effect on damaged hair.
[0004]
[Problems to be solved by the invention]
The present inventors have result of intensive investigations in view of such circumstances, obtained by performing an extraction operation from the cuticle, specific proteins constituting the surface layer of the hair of the components of the protein eluted by damage of the hair The present invention is completed by finding that the protein can be efficiently produced by extracting the hair with a buffer containing a reducing agent, and that the protein is useful as a hair treatment agent containing the protein. be those leading to, its object is useful in hair damage prevention or damage hair repair, to provide a hair treatment agent.
[0005]
[Means for Solving the Problems]
Therefore, the above-mentioned object is to obtain an extract derived from a hair dermis extracted from a hair dermis of a mammal , or a hair dermis derived extract obtained by modifying all or part of the SH group of a protein. It is achieved by a hair treatment agent characterized by compounding.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the configuration of the present invention will be described in detail.
[0007]
As a method obtaining the cuticle (cuticle) used in the present invention include a method that may be separated from the known hair. For example, the hair can be physically peeled off by shaking in water, stirring or ultrasonication (see Journal of the Society of Cosmetic Chemists, 25, 13, 1974). Exfoliated cuticle, by filtration through a gauze or mesh, after separation from the hair, can be collected by centrifugation or filtration. The hair used in the present invention includes human hair, wool, pig hair and the like.
[0008]
As a method for producing cuticle from extracts of the invention, the cuticle obtained by separation from the example collected hair hair, buffer containing only (1) a reducing agent, (2) a reducing agent and soluble Examples include a method of extracting with an extract such as a buffer containing a solubilizer. In particular, when performing the extraction with a buffer containing only the reducing agent (1), it is possible to obtain with less inclusions cuticle derived extract preferably.
[0009]
Extraction operation, performing solution of extraction buffer hair small skin by alkaline. It is preferable that the temperature is 25 to 100 ° C.
[0010]
Also, either when manufacturing the cuticle derived extract from cuticle is stirred a cuticle in extract and the cuticle crush rubs in the extract by using a homogenizer or the like, efficiently present invention the preferred hair cuticle from the extract obtained in.
[0011]
Examples of the reducing agent used in the present invention include mercaptoethanol, dithiothreitol, sodium sulfite, ammonium thioglycolate and the like.
[0012]
The concentration of the reducing agent used in the present invention alone is preferably 1 to 3% by weight of the total amount of the buffer solution.
[0013]
As the solubilizer used in the extract, well-known and publicly known solubilizers, solubilizers such as surfactants can be used. Examples of the denaturants include urea, guanidine hydrochloride, and the like. Is sodium dodecyl sulfate.
[0014]
As hair methods for making a small skin extract derived from derivatives of the present invention, a protein SH groups contained in the cuticle from the extract of the present invention for example, include conventional methods for modifying with monoiodoacetic acid and ethylene imine It is done.
[0015]
Cuticle extract derived from derivatives of the present invention can be applied to a wide range because even in the absence of a reducing agent and a solubilizer are dissolved in water.
[0016]
Cuticle derived extract of the present invention, and since cuticle derived extract derivative itself is a protein that contains a large amount of S-S bridge or SH group, directly shampoos, rinses, hair treatment agents such as hair treatments It can also be used as a protective component for hair by blending.
[0017]
Cuticle derived extract of the present invention, treatment is as dosage form for hair treatment comprising a cuticle derived extract derivative, rinse, shampoo, hair cream, hair lotion, hair pack, permanent dosage etc., to the hair And various types used.
[0018]
The content of cuticle from the extract and cuticle extract derived from derivatives of the present invention may comprise from 0.01% to 5% preferably 0.1% to 1% by weight based on the total amount of the composition are particularly preferred.
[0019]
In addition, cuticle derived extract of the present invention, and cuticle extract derived from derivatives are useful, for example, as an antigen when producing an antibody that specifically recognizes the cuticle.
[0020]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples.
[0021]
Production Examples 1, 2 and Reference Examples 1 and 2 (preparation of cuticle derivative extracts cuticle derived extract derivative, cuticle specific proteins and cuticle specific protein derivatives from human cuticle)
(1) Human cuticle 800 mg, was added to 0.2M Tris (pH 9.5) 3 ml containing 8M urea and 0.2M 2-mercaptoethanol and incubated 50 ° C. 1 hour, crushed rubbed using a glass homogenizer. After further incubation 50 ° C. 1 h, the supernatant collected by centrifugation (10,000 g), cuticle derived extract (21 mg as protein mass; Production Example 1) was obtained.
[0022]
(2) In addition the monoiodoacetic acid 75mg to half of the cuticle from extract (Production Example 1), and pH 9.0 with Tris, and 1.5 hr stirring in the dark at room temperature. 10mM Tris - give the hydrochloride buffer cuticle derived extract was dialyzed against (pH 8.0) (carboxymethylated) derivative (preparation 2).
[0023]
(3) cuticle specific proteins and their cuticle specific protein (carboxymethylated) derivatives were separated by SDS- polyacrylamide electrophoresis. The resulting Production Example 1 or 2 of extract by above was electrophoresed by using a 15% gel containing 6M urea, and transferred to a polyvinylidene difluoride (PVDF) membrane, resulting cuticle extract cut a molecular weight of about 7,000 bands and molecular weight of about 15,000 band of the cuticle extract derivative of a product, acetic acid / acetonitrile / water and extracted with a mixed solution of (7: 2: 1), cuticle specific proteins (reference example 1) and was obtained cuticle specific protein (carboxymethylated) derivative (reference example 2).
[0024]
After cuticle specific protein on the PVDF membrane (carboxymethylated) derivative was treated with 0.5% polyvinyl pyrrolidone and reacted at 24 hours 37 ° C. was added trypsin (Promega). The resulting degradation product was subjected to reverse phase liquid chromatography under the following conditions, and fractions having retention times of 14.2 minutes and 18.3 minutes were collected.
[0025]
Column: A-312 ODS (6.O x 150 mm, YMC)
Elution: Water-acetonitrile-trifluoroacetic acid (90: 10: 0.1) to water-acetonitrile-trifluoroacetic acid (30: 70: 0.1) linear concentration gradient (concentration gradient over 60 minutes)
Flow rate: 2.O ml / min
Detection: Absorbance at 220 nm
The obtained fraction was dried under reduced pressure, and then the amino acid sequence was analyzed with a 471A gas phase protein sequencer manufactured by Applied Biosystems. The following results were obtained.
[0027]
Results of amino acid sequence analysis of a fraction with a retention time of 14.2 minutes:
[0028]
[Chemical 1]
Results of amino acid sequence analysis of the fraction with a retention time of 18.3 minutes:
[0030]
[Chemical 2]
(However, X is an unidentified amino acid.)
[0032]
Production Examples 3 and 4 and Reference Examples 3 and 4 (manufacture of cuticle derivative extracts cuticle derived extract derivative, cuticle specific proteins and cuticle specific protein derivatives from human cuticle)
But using human cuticle 100 mg, in the same manner as in Preparation Example 1, 2 and Reference Examples 1 and 2, cuticle from extracts from human cuticle, cuticle extract derived from derivatives, hair Small It was produced skin-specific protein and cuticle specific protein derivatives (
[0033]
The obtained fraction was dried under reduced pressure, and then the amino acid sequence was analyzed with a 471A gas phase protein sequencer manufactured by Applied Biosystems. The following results were obtained.
[0034]
Results of amino acid sequence analysis of a fraction with a retention time of 14.2 minutes:
[0035]
[Chemical 3]
Results of amino acid sequence analysis of the fraction with a retention time of 18.3 minutes:
[0037]
[Formula 4]
Production Example 5 (Production of cuticle from the extract by denaturing and reducing agents containing buffer)
The 800 mg human cuticle, in addition to 0.2M Tris (pH 9.5) 3 ml containing 8M urea and 0.2M 2-mercaptoethanol and incubated 50 ° C. 1 hour, crushed rubbed using a glass homogenizer. After further incubation at 50 ° C. for 1 hour, the supernatant was collected by centrifugation (10,000 g). The residue is triturated with a glass homogenizer, after incubation 50 ° C. 1 h, the operation of collecting the centrifuged (10,000 g) and the supernatant, repeated six times, from cuticle collecting resulting supernatant An extract (21 mg as protein mass) was obtained.
[0039]
Production Example 6 (Production of cuticle from the extract with a surfactant and a reducing agent-containing buffer solution)
As a solution for extracting the human cuticle, 0.2 M Tris (pH 9.0) containing 2% sodium dodecyl sulfate and 10mM dithiothreitol except using 3ml in the same manner as in Production Example 5, cuticle derived extract (protein 15 mg) was obtained.
[0040]
Production Example 7 (Production of cuticle from the extract with a reducing agent-containing buffer from human cuticle)
As a solution for extracting the human cuticle, 0.2 M Tris (pH 9.5) containing 0.2 M 2-mercaptoethanol except using 3ml in the same manner as in Production Example 5, cuticle derived extract (8.9 mg as protein content )
[0041]
Reference Example 5 (Production of hair cuticle-specific protein fractions by the perm solution of all hair)
2.5 g of human hair was immersed in Perm 1st liquid (12% ammonium thioglycolate, 1% ethanolamine, 0.05% sodium ethylenediaminetetraacetate, 0.42% aqueous ammonia) for 15 minutes at room temperature. 5 times to replace the permanent first liquid collected eluant to afford an ultrafiltration membrane and concentrated using a cuticle-specific protein fraction (0.13 mg as protein mass).
[0042]
Production Examples 8, 9 and Reference Examples 6 and 7 (cuticle from extracts from wool cuticle, production of cuticle from extract derivative, cuticle specific proteins and cuticle specific protein derivatives)
Using wool cuticle 200mg, in the same manner as in Production Example 1, 2 and Reference Examples 1 and 2 (1), cuticle derived extract (5.2 mg as protein mass; Production Example 8) was obtained.
[0043]
Another added 25mg is a monoiodoacetic acid to half of the cuticle from extract (Preparation Example 8), in the same manner as in Production Example 1, 2 and Reference Examples 1 and 2 (2), cuticle extract derived from A product (carboxymethylated) derivative ( Production Example 9 ) was obtained.
[0044]
Cuticle specific proteins and their cuticle specific protein (carboxymethylated) derivatives were separated by SDS- polyacrylamide electrophoresis. The resulting preparation 8 or 9 extracts the above, was electrophoresed by using a 15% gel containing 6M urea, resulting hair molecular weight of about 7,000 bands and their cuticle Extraction of cuticle extract cut a molecular weight of about 15,000 band of articles derivatives, protein dissolution apparatus (ISCO, Inc., 1750) was extracted using a cuticle-specific proteins (reference example 6) and cuticle specific protein (carboxymethylated) derivative ( Reference Example 7 ) was obtained.
[0045]
The obtained fraction was hydrolyzed with 6M hydrochloric acid, and amino acids were analyzed with an amino acid analyzer manufactured by Hitachi. The following results were obtained. The cysteine content is a quantitative value as cysteic acid obtained by hydrolysis after formic acid oxidation in Reference Example 6 , and as S-carboxymethylcysteine in Reference Example 7 .
[0046]
[Table 1]
Comparative Production Example 1 ( Production of fur- derived extract with a denaturing agent and a reducing agent-containing buffer)
As the raw material, the hair except the hair cuticle, ie except for using cortex 800mg in the same manner as in Preparation Example 1 to obtain a soluble extract (160 mg as a protein amount).
[0048]
Test Example 1 (protein analysis)
Cuticle derived extract and cuticle specific protein fraction (
[0049]
In Production Examples 1 , 2 , 6 , 7 , and 8, low molecular weight protein bands were observed, whereas in Comparative Production Example 1, they were not observed.
[0050]
Test Example 2 (protein analysis)
In the same manner as in Test Example 1, the proteins of Production Examples 5 , 6 , 7 and Comparative Production Example 1 were analyzed, and the results are shown in FIG.
[0051]
In Production Examples 5 , 6 , and 7 , low molecular weight protein bands were observed, whereas in Comparative Production Example 1, they were not observed.
[0052]
Test Example 3 (analysis of the hair cuticle-specific protein)
Analysis of cuticle from hair extract cuticle specific proteins using specific antibodies against cuticle specific proteins was carried out by Western blotting. The specific antibody against cuticle specific proteins using the antiserum obtained by immunizing peptide antigen obtained by, based on the amino acid sequence synthesis.
[0053]
As here antigens, using multiple antigenic peptides with synthesized having the following structure based on the partial amino acid sequence of the cuticle-specific proteins.
[0054]
[Chemical formula 5]
Antiserum obtained by immunizing rabbits with 250 μg of
[0056]
[0057]
While both in the manufacturing example 1,2,6,7,8 binding of anti-cuticle specific protein specific antibodies to protein bands of lower molecular observed, it was not observed in Comparative Production Example 1. Therefore, it is clear cuticle from extracts of
[0058]
Test Example 4 (analysis of the hair cuticle-specific protein)
In the same manner as in Test Example 3, the result of performing an analysis of cuticle specific proteins of Preparation 5-7, shown in FIG.
[0059]
While both in the manufacturing example 5-7 binding of anti-cuticle specific protein specific antibodies to protein bands of lower molecular observed, it was not observed in Comparative Production Example 1. Therefore, it is clear cuticle from extracts of
[0060]
Examples 1-5 (cuticle derived extract-containing hair treatment)
Dissolved cuticle derived extracts prepared in Preparation Examples 1,2,6,7,8 and cuticle derived extract derivative 10mg physiological phosphate buffer 1ml containing 20mM2- mercaptoethanol, from cuticle An extract- containing hair treatment agent for hair damage repair (Examples 1 to 5 ) was prepared.
[0061]
Test Example 5 (Repair effect on damaged hair)
Previously, the 7 bundles hair subjected 3 times the permanent process, it was immersed for 30 minutes each at room temperature cuticle derived extract-containing hair damage repair agents of Examples 1 to 5 was washed with water. A knot was made on each of the three types of untreated hair (healthy hair), perm treated hair before and after treatment with the restoration agent so that cuticle wrinkles could be easily observed, and observed with a scanning electron microscope. It was observed that the curl of the cuticle observed in the perm-treated hair was restored to the level of healthy hair by treatment with any treatment agent.
[0062]
Example 6-11 (cuticle derived extract-containing hair treatment agent)
Having the following composition, the hair obtained in Production Example 1,2,6,7,8,9 cuticle derived extract and cuticle derived extract derivative hair treatment agent containing (Example 6-11) Prepared.
[0063]
[Table 2]
Test Example 6 (Sensory Test of cuticle from extract-containing hair treatment agent)
After 1 hour immersion human hair bundle (black hair 5g) in cuticle derived extract-containing hair treatment agent of Example 6 to 11, air-dried and washed with running water for 10 minutes. Combing of processing after the hair bundle, suppleness, comb towards the pre-treatment of the hair bundle and the result of which makes a good or sensory evaluation, the hair bundle both treated with the hair cuticle from the extract-containing hair treatment agent for feeling Street, suppleness and texture were good.
[0065]
Application Example 1 (hair hair diagnostic kit using a small skin-derived extract)
A hair diagnosis kit composed of the four types of solutions described below was prepared, and the degree of damage was diagnosed with human hair.
[0066]
A solution: the cuticle extract derived from 1mg obtained in Production Example 7, 3 weeks every 4 times, FCA (at first immunization) or, immunizing a rabbit with FIA (time booster), 10 weeks after the first immunization Antiserum obtained by whole blood collection was prepared by diluting 1,000 times with PBS containing 0.05
[0067]
Solution B: Peroxidase-labeled goat anti-rabbit IgG antibody (manufactured by Kappel) was prepared by diluting 7,000 times with PBS containing 0.05% Tween20.
[0068]
Solution C: 0.2 M disodium phosphate-0.1 M citrate buffer solution containing 20 mg orthophenylenediamine and 10 μl hydrogen peroxide, pH 5.0 (peroxidase substrate solution)
[0069]
D liquid: physiological saline [0070]
The solution A was added to 10 mg of hair of a person with damaged hair and a healthy person and incubated at 37 ° C. for 1 hour. After washing 6 times with solution D, it was incubated with solution B for 30 minutes at room temperature. After washing 6 times with solution D, when solution C was added, the test tube containing the damaged person's hair developed color.
[0071]
From the above results, an antibody was obtained cuticle derived extract as an antigen, it is clear that it is possible to know the damage state or health of the hair.
[0072]
In addition, when the solution A was added and incubated at 37 ° C. for 1 hour, the damaged hair also showed an effect of repairing damage such as rejuvenation. Therefore, antibodies to the cuticle from extracts of the present invention was obtained as an antigen, was found to be useful in the repair and prevention of damage to the hair.
[0073]
【The invention's effect】
From the above results, the present invention, as a marker know damage conditions or the health of the hair, or useful as damage hair repair and prophylactic material, cuticle derivative extracts cuticle extract derived from derivatives and, It is clear that a hair treatment agent containing the extract can be provided.
[Brief description of the drawings]
[1] cuticle derived extract, the cuticle extract derived from derivatives and cortex-derived extract, SDS-polyacrylamide electrophoresis (6M urea presence, 15% gel) was separated by Coomassie Brilliant proteins It is a drawing substitute photograph dye | stained with blue (CBBG).
The arrow indicates the band of hair cuticle-specific protein.
The arrow indicates the band of hair cuticle-specific protein.
The arrow indicates the band of hair cuticle-specific protein.
The arrow indicates the band of hair cuticle-specific protein.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24137996A JP4194669B2 (en) | 1995-10-20 | 1996-08-22 | Hair treatment agent |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7-297660 | 1995-10-20 | ||
| JP29766095 | 1995-10-20 | ||
| JP24137996A JP4194669B2 (en) | 1995-10-20 | 1996-08-22 | Hair treatment agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09169800A JPH09169800A (en) | 1997-06-30 |
| JP4194669B2 true JP4194669B2 (en) | 2008-12-10 |
Family
ID=26535230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24137996A Expired - Fee Related JP4194669B2 (en) | 1995-10-20 | 1996-08-22 | Hair treatment agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4194669B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101886991A (en) * | 2010-06-10 | 2010-11-17 | 宁波大学 | A kind of preparation method of two-dimensional electrophoresis squid ink sac whole protein sample |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4824370B2 (en) * | 2004-09-27 | 2011-11-30 | 中野製薬株式会社 | Hair treatment agent |
| JP4881567B2 (en) * | 2005-03-10 | 2012-02-22 | 中野製薬株式会社 | Styling cosmetics |
| JP4824507B2 (en) * | 2006-08-31 | 2011-11-30 | 中野製薬株式会社 | Straight perm agent |
| JP5411655B2 (en) * | 2008-12-03 | 2014-02-12 | 株式会社ミルボン | Hair treatment method and hair treatment agent |
| JP5558034B2 (en) * | 2009-06-12 | 2014-07-23 | 株式会社ミルボン | Hair care agent and hair treatment method |
| KR101951923B1 (en) * | 2009-06-12 | 2019-02-25 | 가부시키가이샤 미르본 | Hair treatment agent and starting material for hair treatment agent |
| EP2572201B1 (en) | 2010-05-17 | 2015-08-26 | The Procter and Gamble Company | Methods of detecting and demonstrating hair damage via evaluation of protein fragments |
-
1996
- 1996-08-22 JP JP24137996A patent/JP4194669B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101886991A (en) * | 2010-06-10 | 2010-11-17 | 宁波大学 | A kind of preparation method of two-dimensional electrophoresis squid ink sac whole protein sample |
| CN101886991B (en) * | 2010-06-10 | 2011-11-23 | 宁波大学 | A kind of preparation method of two-dimensional electrophoresis squid ink sac whole protein sample |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09169800A (en) | 1997-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2879947B2 (en) | Hair modifier | |
| JPH06227955A (en) | Hair dye or cosmetic and pretreating agent and method for dyeing hair | |
| JP3227317B2 (en) | Hair dye pretreatment agent, hair dye pretreatment cosmetic, and hair dyeing method | |
| JP4194669B2 (en) | Hair treatment agent | |
| JPH0848698A (en) | Peptide composition derivatized from yeast protein, its production and its use | |
| Kon et al. | Analysis of the damaged components of permed hair using biochemical technique | |
| EP0542309B1 (en) | Hair care product | |
| Carstairs et al. | Immunogenic contaminants in mouse nerve‐growth factor | |
| JPH07330556A (en) | Hair pretreatment and hair cosmetic and hair dyeing method | |
| Husby et al. | Structural similarities between a protein extracted from normal human tissues and a component of amyloid fibrils | |
| JP2942406B2 (en) | Method for producing antibody and hair modifying agent | |
| JP2878287B2 (en) | Cosmetic base material | |
| JPH08143431A (en) | Pretreating agent for dyeing hair | |
| JP3168128B2 (en) | Method for insolubilizing soluble keratin, hair modifying agent and hair modifying method | |
| JP3272892B2 (en) | Method for insolubilizing soluble keratin, method for modifying hair, and hair modifying agent | |
| Teglia et al. | Proteins in cosmetics | |
| JPH06116295A (en) | Protein, antibody and hair-modifying agent | |
| JP2942407B2 (en) | Hair modifier and antibody | |
| JPH08198730A (en) | Hair pretreating agent, hair pretreating cosmetic and hair dyeing method | |
| JPH06116291A (en) | Protein, antibody and hair modifier | |
| JPH06116292A (en) | Protein, antibody and hair modifier | |
| JPH06116294A (en) | Protein, antibody and hair modifier | |
| JPH06116293A (en) | Protein, antibody and hair modifier | |
| JPH11269045A (en) | Hair-protecting agent | |
| JPH05279231A (en) | Hair modifying agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040629 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040805 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040830 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050517 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051004 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060328 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080924 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |